Literature DB >> 15379664

The use of radiolabeled compounds for ADME studies in discovery and exploratory development.

P H Marathe1, W C Shyu, W G Humphreys.   

Abstract

Radiolabeled compounds are excellent investigative tools and widely used to carry out ADME studies during drug discovery and development stages. The most commonly used radioisotopes are 14C and 3H. 3H materials are generally easier to synthesize than 14C materials. Therefore, a variety of probes and substrates used in in vitro assays are labeled with 3H. Since synthesis of 14C material requires intensive resources, it is usually not available until after a molecule is considered for potential development or after the molecule enters the development phase. Improvement in the technology in radiochemistry has enabled the use of radiolabeled compounds earlier in pre-clinical and clinical development to address mechanistic issues. For in vitro studies, radiolabeled probes are utilized to test affinity with various transporters, to perform metabolism comparison among species and to assess possible formation of reactive metabolites. For in vivo studies, radiolabeled compounds are employed to identify and elucidate metabolites formed, to investigate the extent of absorption, bioavailability, tissue distribution, mass balance, routes of excretion, and pre-systemic metabolism. Due to the significant impact of radiolabeled studies on drug development, these studies will be performed earlier than have been in the past and will continue to be an integral part of drug discovery and development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15379664     DOI: 10.2174/1381612043383494

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  9 in total

1.  Excretion of [3H]triptolide and its metabolites in rats after oral administration.

Authors:  Jia Liu; Xin Zhou; Xiao-yan Chen; Da-fang Zhong
Journal:  Acta Pharmacol Sin       Date:  2014-03-17       Impact factor: 6.150

2.  Biodistribution, pharmacokinetics, and nuclear imaging studies of 111In-labeled rGel/BLyS fusion toxin in SCID mice bearing B cell lymphoma.

Authors:  Xiaoxia Wen; Mi-Ae Lyu; Rui Zhang; Wei Lu; Qian Huang; Dong Liang; Michael G Rosenblum; Chun Li
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

3.  Site-Selective Silver-Catalyzed C-H Bond Deuteration of Five-Membered Aromatic Heterocycles and Pharmaceuticals.

Authors:  Adrian Tlahuext-Aca; John F Hartwig
Journal:  ACS Catal       Date:  2021-01-10       Impact factor: 13.700

4.  Optimization of lycopene extraction from tomato cell suspension culture by response surface methodology.

Authors:  Chi-Hua Lu; Nancy J Engelmann; Mary Ann Lila; John W Erdman
Journal:  J Agric Food Chem       Date:  2008-08-09       Impact factor: 5.279

5.  Palladium/Rhodium Cooperative Catalysis for the Production of Aryl Aldehydes and Their Deuterated Analogues Using the Water-Gas Shift Reaction.

Authors:  Malek Y S Ibrahim; Scott E Denmark
Journal:  Angew Chem Int Ed Engl       Date:  2018-07-17       Impact factor: 15.336

6.  Iron-catalysed tritiation of pharmaceuticals.

Authors:  Renyuan Pony Yu; David Hesk; Nelo Rivera; István Pelczer; Paul J Chirik
Journal:  Nature       Date:  2016-01-14       Impact factor: 49.962

Review 7.  Late-Stage Carbon-14 Labeling and Isotope Exchange: Emerging Opportunities and Future Challenges.

Authors:  Victor Babin; Frédéric Taran; Davide Audisio
Journal:  JACS Au       Date:  2022-06-07

8.  Nanotracing and cavity-ring down spectroscopy: A new ultrasensitive approach in large molecule drug disposition studies.

Authors:  Nicole A Kratochwil; Stephen R Dueker; Dieter Muri; Claudia Senn; HyeJin Yoon; Byung-Yong Yu; Gwan-Ho Lee; Feng Dong; Michael B Otteneder
Journal:  PLoS One       Date:  2018-10-17       Impact factor: 3.240

9.  Palladium-Catalyzed Nondirected Late-Stage C-H Deuteration of Arenes.

Authors:  Mirxan Farizyan; Arup Mondal; Sourjya Mal; Fritz Deufel; Manuel van Gemmeren
Journal:  J Am Chem Soc       Date:  2021-09-28       Impact factor: 15.419

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.